Stoke Therapeutics (STOK) Expected to Announce Earnings on Monday

Posted by on Jul 29th, 2026

Stoke Therapeutics (NASDAQ:STOK – Get Free Report) is anticipated to announce its Q2 2026 results before the market opens on Monday, August 3rd. Analysts expect Stoke Therapeutics to post earnings of ($0.82) per share and revenue of $4.89 million for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning report page for the latest details on the call scheduled for Monday, August 3, 2026 at 4:30 PM ET.

Stoke Therapeutics (NASDAQ:STOK – Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported ($0.79) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.01. The business had revenue of $6.23 million for the quarter, compared to the consensus estimate of $6.48 million. Stoke Therapeutics had a negative return on equity of 48.84% and a negative net margin of 529.20%. On average, analysts expect Stoke Therapeutics to post $-3 EPS for the current fiscal year and $-3 EPS for the next fiscal year.

Stoke Therapeutics Stock Down 0.7%

Shares of Stoke Therapeutics stock traded down $0.20 on Wednesday, reaching $29.20. The company’s stock had a trading volume of 52,228 shares, compared to its average volume of 729,563. Stoke Therapeutics has a 52 week low of $12.40 and a 52 week high of $40.22. The firm’s fifty day simple moving average is $30.40 and its two-hundred day simple moving average is $32.06. The company has a market capitalization of $1.82 billion, a price-to-earnings ratio of -10.39 and a beta of 1.17.

Insider Buying and Selling

In other Stoke Therapeutics news, insider Barry Ticho sold 1,795 shares of the company’s stock in a transaction on Monday, June 1st. The stock was sold at an average price of $30.58, for a total transaction of $54,891.10. Following the completion of the sale, the insider owned 34,826 shares in the company, valued at $1,064,979.08. This represents a 4.90% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, General Counsel Jonathan Allan sold 1,457 shares of the stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $29.95, for a total value of $43,637.15. Following the sale, the general counsel directly owned 18,086 shares in the company, valued at $541,675.70. This trade represents a 7.46% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 9.60% of the company’s stock.

Hedge Funds Weigh In On Stoke Therapeutics

Large investors have recently added to or reduced their stakes in the company. Janus Henderson Group PLC boosted its holdings in shares of Stoke Therapeutics by 333.8% in the 4th quarter. Janus Henderson Group PLC now owns 1,450,933 shares of the company’s stock valued at $46,031,000 after buying an additional 1,116,452 shares in the last quarter. State Street Corp boosted its position in shares of Stoke Therapeutics by 75.2% in the 4th quarter. State Street Corp now owns 2,498,049 shares of the company’s stock worth $79,288,000 after purchasing an additional 1,072,176 shares in the last quarter. Corient Private Wealth LLC purchased a new position in Stoke Therapeutics during the 2nd quarter worth $7,489,000. Wellington Management Group LLP increased its position in Stoke Therapeutics by 438.2% during the 3rd quarter. Wellington Management Group LLP now owns 737,753 shares of the company’s stock valued at $17,337,000 after buying an additional 600,687 shares in the last quarter. Finally, Polar Capital Holdings Plc raised its stake in Stoke Therapeutics by 49.8% in the third quarter. Polar Capital Holdings Plc now owns 1,323,470 shares of the company’s stock valued at $31,102,000 after buying an additional 439,824 shares during the last quarter.

Wall Street Analysts Forecast Growth

STOK has been the topic of several analyst reports. Weiss Ratings cut shares of Stoke Therapeutics from a “hold (c)” rating to a “sell (d)” rating in a research note on Monday, May 11th. The Goldman Sachs Group initiated coverage on shares of Stoke Therapeutics in a report on Monday, July 13th. They issued a “buy” rating and a $44.00 price target on the stock. Finally, BTIG Research reaffirmed a “buy” rating and set a $39.00 price target on shares of Stoke Therapeutics in a research note on Monday, May 11th. Nine research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $43.00.

Check Out Our Latest Analysis on Stoke Therapeutics

Stoke Therapeutics Company Profile

(Get Free Report)

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.

Featured Articles

Earnings History for Stoke Therapeutics (NASDAQ:STOK)

Receive News & Ratings for Stoke Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stoke Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.